What adjustments should be made to a type 2 diabetes patient's gliclazide (sulfonylurea) MR medication regimen during Ramadhan fasting?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Gliclazide MR Dosing Adjustment for Ramadan

For patients on once-daily gliclazide MR, shift the entire dose from morning to evening (before the sunset meal/Iftar) without any dose reduction. 1, 2

Dosing Strategy Based on Baseline Regimen

Once-Daily Gliclazide MR (e.g., 60 mg)

  • Take the full dose before the sunset meal (Iftar) with no dose reduction required 1, 2
  • This simple timing shift maintains glycemic control while minimizing hypoglycemia risk 3, 4
  • After Ramadan ends, immediately return to the pre-Ramadan morning schedule 2

Twice-Daily Standard Gliclazide (e.g., 80 mg twice daily)

  • Take half the usual morning dose at the predawn meal (Suhur) and the full dose at the sunset meal (Iftar) 1, 2
  • Example: If taking gliclazide 80 mg twice daily, adjust to 40 mg at Suhur and 80 mg at Iftar 1

Pre-Ramadan Preparation (6-8 Weeks Before)

Conduct structured risk stratification and patient education 2:

  • Evaluate glycemic control (HbA1c), renal function, and hepatic status 2
  • Assess for history of recurrent hypoglycemia or hypoglycemia unawareness—these patients should avoid fasting 5
  • Provide education on recognizing hypoglycemia/hyperglycemia symptoms and when to break the fast 2
  • Consider trial fasting to test the medication regimen before Ramadan begins 6

Critical Monitoring During Ramadan

Self-monitor blood glucose closely during the first 3-4 weeks 2, 5:

  • Check glucose in the first few hours after starting the fast 2
  • Check again in late afternoon before breaking fast 2
  • Break the fast immediately if blood glucose drops below 70 mg/dL 6

Evidence Supporting Safety

The real-world DIA-RAMADAN study of 1,244 patients demonstrated that gliclazide MR during Ramadan resulted in only 2.2% experiencing symptomatic hypoglycemia with zero severe hypoglycemic events 4. The Bangladeshi sub-analysis specifically showed that switching gliclazide MR 60 mg from morning to evening dosing maintained glycemic control with no severe hypoglycemia 3. A controlled trial in 136 male patients confirmed that evening administration of gliclazide MR 60 mg maintained glycemic control with only 2.2% experiencing hypoglycemia during the fast 7.

Common Pitfalls to Avoid

  • Do not excessively reduce the gliclazide dose—this causes rebound hyperglycemia and increases diabetic ketoacidosis risk 2
  • Do not use chlorpropamide during Ramadan due to high risk of prolonged, unpredictable hypoglycemia 5
  • Do not continue morning dosing—the timing shift to evening is essential for safety 1, 7

Nutritional Strategy

Distribute calories over two to three smaller meals during the non-fasting interval to prevent excessive postprandial hyperglycemia 2, 5. Ensure adequate fluid intake during non-fasting hours 1, 5.

Post-Ramadan Management

Return gliclazide to the pre-Ramadan morning schedule immediately after Ramadan ends 2. Assess overall health, complications, and glycemic control to evaluate how well the patient tolerated fasting and guide future Ramadan planning 2, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Medication Management for Ramadan Fasting in Patients with Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Intermittent Fasting: Cardiovascular and Metabolic Benefits and Risks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

DPP-4 Inhibitors for Ramadan Fasting Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.